OpenAI 收购 Orchestra Bio，将并入 Rosalind 生命科学模型与工具
摘要
OpenAI 宣布收购 Orchestra Bio，该平台用于帮助生物制药团队协调复杂的药物开发流程。OpenAI 表示将在此基础上发展面向生命科学研究的 Rosalind 模型与工具，以简化这些流程、让新疗法更快到达患者。Greg Brockman 转发该消息并称，加速药物开发是其模型一个令人兴奋且有前景的新兴应用方向。详情见 https://openai.com/index/openai-to-acquire-orchestra-bio/
摘要由模型根据原文撰写，以原文为准。
正文 · 原文
towards acceleration of drug development, an extremely exciting and promising emerging application of our models
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! https://openai.com/index/openai-to-acquire-orchestra-bio/在 X 查看被引用的帖子
来源：Greg Brockman · x.com
引用原文
gdb. towards acceleration of drug development, an extremely exciting and promising emerging application of our models[EB/OL]. (2026-10-21)[访问日期]. https://x.com/gdb/status/2112797730829697108.